Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1995 Jun;115(3):421–426. doi: 10.1111/j.1476-5381.1995.tb16350.x

Biphasic inhibition of stimulated endogenous dopamine release by 7-OH-DPAT in slices of rat nucleus accumbens.

J Patel 1, S J Trout 1, P Palij 1, R Whelpton 1, Z L Kruk 1
PMCID: PMC1908402  PMID: 7582452

Abstract

1. Fast cyclic voltammetry was used to investigate the effect of 7-OH-DPAT (7-hydroxy-N,N-di-n-propyl-2-aminotetralin), a putative D3 receptor agonist, on electrically stimulated endogenous dopamine release in slices of rat nucleus accumbens. 2. 7-OH-DPAT inhibited single pulse stimulated dopamine release in a concentration-dependent manner with a maximum inhibition of 95.5%. Analysis of concentration-response curves to 7-OH-DPAT showed that they were biphasic, with the high affinity component contributing 18.0% to the total inhibition and the low affinity component 77.5%. 7-OH-DPAT exhibited a 560 fold selectivity between the high and low affinity components (0.015 nM compared to 8.4 nM). 3. Concentration-response curves to the non-selective D2/D3 agonist, apomorphine, were monophasic. The maximum inhibition was 93.1% and the EC50 value 82 nM. 4. The selective D2 antagonist, haloperidol (30 nM), antagonized the low affinity component of the concentration-response cuve to 7-OH-DPAT whilst the high affinity component was essentially unaffected. The pKB values calculated for the high and low affinity components were 7.89 and 9.45 respectively. 5. In conclusion, these results demonstrate that 7-OH-DPAT inhibits stimulated dopamine release by acting at two different sites. Furthermore, the results are consistent with the hypothesis that the high and low affinity components of the concentration-response curve to 7-OH-DPAT may reflect activation of functional D3 and D2 release-regulating autoreceptors respectively. However, the possibility that the biphasic nature of the curve may reflect different subtypes of the D2 receptor cannot be excluded.

Full text

PDF
421

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baldessarini R. J., Kula N. S., McGrath C. R., Bakthavachalam V., Kebabian J. W., Neumeyer J. L. Isomeric selectivity at dopamine D3 receptors. Eur J Pharmacol. 1993 Aug 3;239(1-3):269–270. doi: 10.1016/0014-2999(93)91011-b. [DOI] [PubMed] [Google Scholar]
  2. Bouthenet M. L., Souil E., Martres M. P., Sokoloff P., Giros B., Schwartz J. C. Localization of dopamine D3 receptor mRNA in the rat brain using in situ hybridization histochemistry: comparison with dopamine D2 receptor mRNA. Brain Res. 1991 Nov 15;564(2):203–219. doi: 10.1016/0006-8993(91)91456-b. [DOI] [PubMed] [Google Scholar]
  3. Bull D. R., Palij P., Sheehan M. J., Millar J., Stamford J. A., Kruk Z. L., Humphrey P. P. Application of fast cyclic voltammetry to measurement of electrically evoked dopamine overflow from brain slices in vitro. J Neurosci Methods. 1990 Apr;32(1):37–44. doi: 10.1016/0165-0270(90)90069-r. [DOI] [PubMed] [Google Scholar]
  4. Bull D. R., Sheehan M. J. Presynaptic regulation of electrically evoked dopamine overflow in nucleus accumbens: a pharmacological study using fast cyclic voltammetry in vitro. Naunyn Schmiedebergs Arch Pharmacol. 1991 Mar;343(3):260–265. doi: 10.1007/BF00251124. [DOI] [PubMed] [Google Scholar]
  5. Caine S. B., Koob G. F. Modulation of cocaine self-administration in the rat through D-3 dopamine receptors. Science. 1993 Jun 18;260(5115):1814–1816. doi: 10.1126/science.8099761. [DOI] [PubMed] [Google Scholar]
  6. Daly S. A., Waddington J. L. Behavioural effects of the putative D-3 dopamine receptor agonist 7-OH-DPAT in relation to other "D-2-like" agonists. Neuropharmacology. 1993 May;32(5):509–510. doi: 10.1016/0028-3908(93)90177-5. [DOI] [PubMed] [Google Scholar]
  7. Freedman S. B., Patel S., Marwood R., Emms F., Seabrook G. R., Knowles M. R., McAllister G. Expression and pharmacological characterization of the human D3 dopamine receptor. J Pharmacol Exp Ther. 1994 Jan;268(1):417–426. [PubMed] [Google Scholar]
  8. Hafizi S., Palij P., Stamford J. A. Activity of two primary human metabolites of nomifensine on stimulated efflux and uptake of dopamine in the striatum: in vitro voltammetric data in slices of rat brain. Neuropharmacology. 1992 Aug;31(8):817–824. doi: 10.1016/0028-3908(92)90046-r. [DOI] [PubMed] [Google Scholar]
  9. Large C. H., Stubbs C. M. The dopamine D3 receptor: Chinese hamsters or Chinese whispers? Trends Pharmacol Sci. 1994 Feb;15(2):46–47. doi: 10.1016/0165-6147(94)90108-2. [DOI] [PubMed] [Google Scholar]
  10. Limberger N., Trout S. J., Kruk Z. L., Starke K. "Real time" measurement of endogenous dopamine release during short trains of pulses in slices of rat neostriatum and nucleus accumbens: role of autoinhibition. Naunyn Schmiedebergs Arch Pharmacol. 1991 Dec;344(6):623–629. doi: 10.1007/BF00174745. [DOI] [PubMed] [Google Scholar]
  11. Lévesque D., Diaz J., Pilon C., Martres M. P., Giros B., Souil E., Schott D., Morgat J. L., Schwartz J. C., Sokoloff P. Identification, characterization, and localization of the dopamine D3 receptor in rat brain using 7-[3H]hydroxy-N,N-di-n-propyl-2-aminotetralin. Proc Natl Acad Sci U S A. 1992 Sep 1;89(17):8155–8159. doi: 10.1073/pnas.89.17.8155. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. MacKenzie R. G., VanLeeuwen D., Pugsley T. A., Shih Y. H., Demattos S., Tang L., Todd R. D., O'Malley K. L. Characterization of the human dopamine D3 receptor expressed in transfected cell lines. Eur J Pharmacol. 1994 Jan 1;266(1):79–85. doi: 10.1016/0922-4106(94)90212-7. [DOI] [PubMed] [Google Scholar]
  13. Milton N. G., Self C. H., Hillhouse E. W. Effects of pyrogenic immunomodulators on the release of corticotrophin-releasing factor-41 and prostaglandin E2 from the intact rat hypothalamus in vitro. Br J Pharmacol. 1993 May;109(1):88–93. doi: 10.1111/j.1476-5381.1993.tb13535.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. O'Connor J. J., Kruk Z. L. Pharmacological characteristics of 5-hydroxytryptamine autoreceptors in rat brain slices incorporating the dorsal raphe or the suprachiasmatic nucleus. Br J Pharmacol. 1992 Jul;106(3):524–532. doi: 10.1111/j.1476-5381.1992.tb14369.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Palij P., Bull D. R., Sheehan M. J., Millar J., Stamford J., Kruk Z. L., Humphrey P. P. Presynaptic regulation of dopamine release in corpus striatum monitored in vitro in real time by fast cyclic voltammetry. Brain Res. 1990 Feb 12;509(1):172–174. doi: 10.1016/0006-8993(90)90329-a. [DOI] [PubMed] [Google Scholar]
  16. Patel J., Trout S. J., Kruk Z. L. Regional differences in evoked dopamine efflux in brain slices of rat anterior and posterior caudate putamen. Naunyn Schmiedebergs Arch Pharmacol. 1992 Sep;346(3):267–276. doi: 10.1007/BF00173539. [DOI] [PubMed] [Google Scholar]
  17. Pilon C., Lévesque D., Dimitriadou V., Griffon N., Martres M. P., Schwartz J. C., Sokoloff P. Functional coupling of the human dopamine D3 receptor in a transfected NG 108-15 neuroblastoma-glioma hybrid cell line. Eur J Pharmacol. 1994 Jul 15;268(2):129–139. doi: 10.1016/0922-4106(94)90182-1. [DOI] [PubMed] [Google Scholar]
  18. Potenza M. N., Graminski G. F., Schmauss C., Lerner M. R. Functional expression and characterization of human D2 and D3 dopamine receptors. J Neurosci. 1994 Mar;14(3 Pt 2):1463–1476. doi: 10.1523/JNEUROSCI.14-03-01463.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Richfield E. K., Penney J. B., Young A. B. Anatomical and affinity state comparisons between dopamine D1 and D2 receptors in the rat central nervous system. Neuroscience. 1989;30(3):767–777. doi: 10.1016/0306-4522(89)90168-1. [DOI] [PubMed] [Google Scholar]
  20. Seabrook G. R., Kemp J. A., Freedman S. B., Patel S., Sinclair H. A., McAllister G. Functional expression of human D3 dopamine receptors in differentiated neuroblastoma x glioma NG108-15 cells. Br J Pharmacol. 1994 Feb;111(2):391–393. doi: 10.1111/j.1476-5381.1994.tb14746.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Sokoloff P., Giros B., Martres M. P., Bouthenet M. L., Schwartz J. C. Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature. 1990 Sep 13;347(6289):146–151. doi: 10.1038/347146a0. [DOI] [PubMed] [Google Scholar]
  22. Starke K., Göthert M., Kilbinger H. Modulation of neurotransmitter release by presynaptic autoreceptors. Physiol Rev. 1989 Jul;69(3):864–989. doi: 10.1152/physrev.1989.69.3.864. [DOI] [PubMed] [Google Scholar]
  23. Svensson K., Carlsson A., Waters N. Locomotor inhibition by the D3 ligand R-(+)-7-OH-DPAT is independent of changes in dopamine release. J Neural Transm Gen Sect. 1994;95(1):71–74. doi: 10.1007/BF01283032. [DOI] [PubMed] [Google Scholar]
  24. Tang L., Todd R. D., Heller A., O'Malley K. L. Pharmacological and functional characterization of D2, D3 and D4 dopamine receptors in fibroblast and dopaminergic cell lines. J Pharmacol Exp Ther. 1994 Jan;268(1):495–502. [PubMed] [Google Scholar]
  25. Tang L., Todd R. D., O'Malley K. L. Dopamine D2 and D3 receptors inhibit dopamine release. J Pharmacol Exp Ther. 1994 Aug;270(2):475–479. [PubMed] [Google Scholar]
  26. Trout S. J., Kruk Z. L. Differences in evoked dopamine efflux in rat caudate putamen, nucleus accumbens and tuberculum olfactorium in the absence of uptake inhibition: influence of autoreceptors. Br J Pharmacol. 1992 Jun;106(2):452–458. doi: 10.1111/j.1476-5381.1992.tb14355.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Waters N., Svensson K., Haadsma-Svensson S. R., Smith M. W., Carlsson A. The dopamine D3-receptor: a postsynaptic receptor inhibitory on rat locomotor activity. J Neural Transm Gen Sect. 1993;94(1):11–19. doi: 10.1007/BF01244979. [DOI] [PubMed] [Google Scholar]
  28. Yamada S., Yokoo H., Nishi S. Differential effects of dopamine agonists on evoked dopamine release from slices of striatum and nucleus accumbens in rats. Brain Res. 1994 Jun 13;648(1):176–179. doi: 10.1016/0006-8993(94)91920-8. [DOI] [PubMed] [Google Scholar]
  29. Yokoo H., Goldstein M., Meller E. Receptor reserve at striatal dopamine receptors modulating the release of [3H]dopamine. Eur J Pharmacol. 1988 Oct 18;155(3):323–327. doi: 10.1016/0014-2999(88)90523-7. [DOI] [PubMed] [Google Scholar]
  30. Zhuang Z. P., Kung M. P., Kung H. F. Synthesis of (R,S)-trans-8-hydroxy-2-[N-n-propyl-N-(3'-iodo-2'-propenyl)amino]tetral in (trans-8-OH-PIPAT): a new 5-HT1A receptor ligand. J Med Chem. 1993 Oct 15;36(21):3161–3165. doi: 10.1021/jm00073a016. [DOI] [PubMed] [Google Scholar]
  31. el Mestikawy S., Glowinski J., Hamon M. Presynaptic dopamine autoreceptors control tyrosine hydroxylase activation in depolarized striatal dopaminergic terminals. J Neurochem. 1986 Jan;46(1):12–22. doi: 10.1111/j.1471-4159.1986.tb12919.x. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES